Literature DB >> 7507805

High concentrations of immunoreactive gliostatin/platelet-derived endothelial cell growth factor in synovial fluid and serum of rheumatoid arthritis.

K Asai1, T Hirano, K Matsukawa, J Kusada, M Takeuchi, T Otsuka, N Matsui, T Kato.   

Abstract

Since neovascularization plays an important role in the propagation of rheumatoid synovitis, we analyzed the concentration of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF), a potent angiogenic and chemotactic factor, in the synovial fluid and serum of rheumatoid arthritis (RA) patients. The immunoreactive GLS/PD-ECGF concentrations (mean value +/- S.D.) in synovial fluid, measured by a sandwich enzyme immunoassay, were significantly higher in RA patients than in osteoarthritis (OA) patients (233.02 +/- 219.40 vs. 9.09 +/- 14.86 ng/g, P < 0.001), and the serum concentrations were also higher in RA patients than in age-matched controls (8.77 +/- 7.60 vs. 3.74 +/- 2.61 ng/ml, P < 0.005). These results suggest that GLS/PD-ECGF may participate in the endothelial proliferation resulting in initiation of the extensive emigration of mononuclear cells and proliferation of the synovial tissues in rheumatoid arthritis, and that the immunoreactive GLS/PD-ECGF in serum as well as synovial fluids may be a useful diagnostic marker of RA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507805     DOI: 10.1016/0009-8981(93)90216-q

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes.

Authors:  Takuma Kusabe; Yuko Waguri-Nagaya; Tomohiro Tanikawa; Mineyoshi Aoyama; Muneyoshi Fukuoka; Masaaki Kobayashi; Takanobu Otsuka; Kiyofumi Asai
Journal:  Rheumatol Int       Date:  2005-07-01       Impact factor: 2.631

2.  FK506 inhibition of gliostatin/thymidine phosphorylase production induced by tumor necrosis factor-α in rheumatoid fibroblast-like synoviocytes.

Authors:  Takaya Yamagami; Yuko Waguri-Nagaya; Kenji Ikuta; Mineyoshi Aoyama; Kiyofumi Asai; Takanobu Otsuka
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

3.  Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes.

Authors:  Tomohiro Tanikawa; Yuko Waguri-Nagaya; Takuma Kusabe; Mineyoshi Aoyama; Kiyofumi Asai; Takanobu Otsuka
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 2.631

Review 4.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

5.  The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes.

Authors:  Kenji Ikuta; Yuko Waguri-Nagaya; Kae Kikuchi; Takaya Yamagami; Masahiro Nozaki; Mineyoshi Aoyama; Kiyofumi Asai; Takanobu Otsuka
Journal:  Arthritis Res Ther       Date:  2012-04-25       Impact factor: 5.156

Review 6.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.

Authors:  L Griffiths; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.

Authors:  P Kabuubi; J A Loncaster; S E Davidson; R D Hunter; C Kobylecki; I J Stratford; C M L West
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

Review 8.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.